Sarepta Therapeutics SRPT

HealthcareMarket cap $2B1 connection

Sarepta develops gene therapies for Duchenne muscular dystrophy - the most common fatal genetic disease in children. Its Elevidys exon-skipping treatment gave hope to thousands of families. Despite regulatory hurdles, Sarepta is the leader in a disease that otherwise has no cure.

Open Sarepta Therapeutics's Company Hub Simulate a merger Supply chain See it on the map

Partners 1

Strategic partnerships, joint products and alliances

CRISPR TherapeuticsHealthcare · $5BCompeting DMD gene therapy approaches

Other Healthcare companies

Eli Lilly Johnson & Johnson AbbVie Novo Nordisk Merck UnitedHealth Thermo Fisher AstraZeneca Amgen Novartis

Embed this on your site

Show Sarepta Therapeutics's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=SRPT" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Sarepta Therapeutics on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.